Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fastenal

77.85
+3.364.51%
Post-market: 77.75-0.0800-0.10%19:31 EST
Volume:4.61M
Turnover:355.34M
Market Cap:44.64B
PE:38.93
High:78.07
Open:76.06
Low:75.30
Close:74.49
Loading ...

Despite Fast-paced Momentum, 8x8 (EGHT) Is Still a Bargain Stock

Zacks
·
11 Feb

Why Fast-paced Mover Noodles & Co. (NDLS) Is a Great Choice for Value Investors

Zacks
·
11 Feb

Inspired Entertainment (INSE) Shows Fast-paced Momentum But Is Still a Bargain Stock

Zacks
·
11 Feb

Despite Fast-paced Momentum, MasTec (MTZ) Is Still a Bargain Stock

Zacks
·
11 Feb

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

Simply Wall St.
·
11 Feb

BGMC International Limited's (HKG:1693) Shares May Have Run Too Fast Too Soon

Simply Wall St.
·
11 Feb

Kwong Man Kee Group Limited's (HKG:8023) Shares May Have Run Too Fast Too Soon

Simply Wall St.
·
11 Feb

Seazen Group Limited's (HKG:1030) Shares May Have Run Too Fast Too Soon

Simply Wall St.
·
11 Feb

Biodexa Says eRapa Gets FDA Fast Track Designation in Familial Adenomatous Polyposis; Shares Rise

MT Newswires Live
·
11 Feb

Biodexa Pharmaceuticals ADRs Rise After Cancer Drug Gets FDA Fast-Track Designation

Dow Jones
·
11 Feb

Tempest Therapeutics Says Amezalpat Receives US FDA Fast Track Status As Treatment for Liver Cancer

MT Newswires Live
·
10 Feb

Fast-paced Momentum Stock Cheesecake Factory (CAKE) Is Still Trading at a Bargain

Zacks
·
10 Feb

Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock

Zacks
·
10 Feb

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

GlobeNewswire
·
10 Feb

Tempest Therapeutics granted FTD from FDA for amezalpat

TIPRANKS
·
10 Feb

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

GlobeNewswire
·
10 Feb